Cantor Fitzgerald analyst Rick Bienkowski upgraded Beam Therapeutics (BEAM) to Overweight from Neutral. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best-performing stocks on TipRanks >> Read More on BEAM: Beam Therapeutics to encore data from BEACON Phase 1/2 trial of Beam-101 Beam Therapeutics Advances Base Editing Portfolio Beam Therapeutics outlines key 2025 anticipated catalysts Beam Therapeutics sees cash runway into 2027 Beam Therapeutics upgraded to Outperform from Market Perform at Bernstein